Tina Kauderer
Family · Castle Rock, CONPI 1366763468
Payments from drug & device makers
Across 264 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Axsome Therapeutics, Inc.$647
- Teva Pharmaceuticals USA, Inc.$462
- Alkermes, Inc.$391
- Otsuka America Pharmaceutical, Inc.$297
- plus $976 from 17 others
What the payments were for
- Food & beverage$4,96798%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,216 |
| AbbVie | 103 | $1,074 |
| Axsome Therapeutics, Inc. | 17 | $647 |
| Teva Pharmaceuticals USA, Inc. | 15 | $462 |
| Alkermes, Inc. | 16 | $391 |
| Otsuka America Pharmaceutical, Inc. | 10 | $297 |
| Johnson & Johnson | 6 | $216 |
| Novo Nordisk | 8 | $138 |
| Idorsia Pharmaceuticals US Inc | 1 | $118 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| Lundbeck LLC | 5 | $85 |
| Bayer | 5 | $74 |
| Sunovion Pharmaceuticals Inc. | 6 | $72 |
| Nevro Corp. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Merck | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,062 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 81 | $120,635 |
| RexultiBrexpiprazole | 78 | $119,807 |
| Invega SustennaPaliperidone Palmitate | 21 | $67,979 |
| CaplytaLumateperone Tosylate | 23 | $39,708 |
| Abilify MaintenaAripiprazole | 12 | $39,147 |
| Oxcarbazepine | 180 | $8,472 |
| Aripiprazole | 196 | $6,594 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 121 | $6,411 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,407 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,368 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 88 | $4,748 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 141 | $4,096 |
| Paliperidone ErPaliperidone | 23 | $2,801 |
| Duloxetine Hcl | 182 | $2,602 |
| Prazosin Hcl | 187 | $2,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $297 | $158,95490 claims |
| AbbVieVraylar | $1,074 | $120,63581 claims |
| Johnson & JohnsonInvega Sustenna | $216 | $67,97921 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,216 | $39,70823 claims |
| Lilly USA, LLCOlanzapine | $15 | $45744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Castle Rock
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.